Top Vaccine Companies Shaping Global Supply in 2026

Top Vaccine Companies Shaping Global Supply in 2026

In September 2026, Sanofi opened a flu vaccine facility in Toronto built with a CAD 925 million investment described as the largest single biomanufacturing investment in Canadian history. It is one signal among many that the top vaccine companies are no longer competing on science alone. They are competing on where doses are made, how fast capacity can be turned on, and who can be relied on when a health system needs supply at short notice.

Our analysis of the global vaccine market puts it at $86.6 billion in 2026, on the way to $126.4 billion by 2033. Here is who is building that capacity, and the record behind each name.

How large is the market these companies serve?

The global vaccine market was valued at $81.9 billion in 2025 and is forecast to reach $126.4 billion by 2033, a compound annual growth rate of 5.572% across that period. For context, the market stood at $65.9 billion in 2021.

That is a market growing steadily rather than explosively which changes what matters. In a steady market, the companies that do well are the ones with durable manufacturing, broad portfolios and long-term public-health relationships, not one-off demand spikes.

How should you judge a vaccine company?

Immunisation is unlike most of pharma. A promising molecule means little if a company cannot make hundreds of millions of sterile doses a year, hold a cold chain across six continents, and satisfy regulators in dozens of jurisdictions at once.

In our market research across the pharma and healthcare cluster, we assess vaccine manufacturers on four capabilities rather than on revenue alone. Each of the companies below is strong on several of them, and each is strong in a different way which is precisely why the market supports all of them.4

• Manufacturing scale — proven annual dose output and surge capacity
• Portfolio breadth — coverage across paediatric, adult and travel indications
• Platform innovation — conjugate, recombinant, live attenuated, viral vector and mRNA capability
• Global access partnerships — WHO prequalification, Gavi, UNICEF and government supply agreement

Who are the top vaccine companies in the global market?

AstraZeneca

AstraZeneca’s distinctive contribution is route of administration. FLUMIST is the only nasal spray influenza vaccine available in the United States, and in September 2024 the FDA approved it for self-administration by adults aged 18 to 49 and caregiver administration for children aged 2 to 17; the first US influenza vaccine cleared for use outside a clinical setting. The company then built a service around that approval: FluMist Home launched in August 2025 across 34 states, with the option available again for the 2026–27 season. Human-factors testing showed 100% of intended users administered a full dose correctly. For a market where convenience strongly influences uptake, that is a meaningful piece of access engineering.

BioNTech SE

BioNTech co-developed Comirnaty, the first approved mRNA vaccine, and has since converted that platform expertise into one of the sector’s deepest research programmes. The company reported approximately €17.2 billion in cash and investments at the end of 2025, and set out plans for 15 Phase 3 trials running by the close of 2026. Its Kigali site in Rwanda built around modular BioNTainer units and supported by EIB and European Commission financing — is positioned to become the continent’s first commercial mRNA facility. That combination of balance-sheet depth, platform fluency and manufacturing localisation gives BioNTech unusual room to invest through a cycle.

Merck & Co Inc

Merck’s strength is the sheer span of its immunisation catalogue: HPV, measles-mumps-rubella, varicella, rotavirus, hepatitis A, Ebola and pneumococcal disease all sit within one portfolio, and the company is the sole US manufacturer of MMRV and varicella vaccines. Its newest pneumococcal vaccine, CAPVAXIVE, recorded $759 million in sales in 2025 and received an expanded FDA indication in August 2026. Few manufacturers can supply as much of a national childhood schedule from a single relationship, which is exactly what procurement teams and health ministries value.

Moderna Inc

Moderna produced the single clearest platform milestone of 2026. On 5 August, the FDA approved mFlusiva — the first mRNA influenza vaccine licensed in the United States with standard approval for adults aged 50 to 64 and accelerated approval for those 65 and older, after the agency’s advisory committee voted unanimously in its favour in June. It joins Spikevax, mNEXSPIKE and mRESVIA, the RSV vaccine now approved in 40 countries. Moderna also licensed mRNA manufacturing sites in Australia and the United Kingdom in 2025 under long-term government agreements, pairing speed of design with sovereign supply.

Pfizer Inc

Pfizer offers one of the broadest adult respiratory and bacterial vaccine franchises in the market. ABRYSVO remains the RSV vaccine with the widest adult indication, extending to adults from 18 upward at increased risk and to infants via maternal immunisation; sales grew 42% in the first half of 2026 to $388 million. Alongside PREVNAR 20 and PENBRAYA, the company brought Phase 3 data on a next-generation 25-valent pneumococcal candidate and a Lyme disease vaccine to IDWeek 2026, and has signalled a 35-valent adult candidate entering development. The pipeline is deliberately built to keep widening coverage.

Sanofi

Sanofi anchors the influenza market and is investing heavily in where that supply physically sits. In September 2026 it inaugurated the Charles Best Building in Toronto, a CAD $925 million end-to-end flu vaccine facility, the largest biomanufacturing investment in Canadian history, supported by federal and Ontario funding and creating roughly 300 skilled jobs. It will produce Fluzone High-Dose for adults aged 65 and over from early 2027. The Toronto campus already ships vaccines to more than 60 countries, and over $2 billion of further infrastructure is planned there by 2028, including a paediatric and booster plant.

Seqirus

A CSL business, Seqirus is built almost entirely around influenza and that focus shows in its preparedness role. Its Holly Springs, North Carolina campus is the world’s largest cell-based influenza vaccine manufacturing site, has delivered around 450 million commercial doses over the past decade, and is contracted to supply up to 150 million pandemic doses within six months of a pandemic declaration. The company completed its 2026–27 manufacturing campaign and announced expanded US availability in September 2026, and opened a new cell-based facility at Tullamarine in Melbourne during FY2026. With sites on three continents and both egg-based and cell-based platforms, it offers genuine supply redundancy.

Serum Institute of India Pvt Ltd

Serum Institute is the world’s largest vaccine manufacturer by dose volume, selling roughly 1.5 billion doses a year against installed capacity of around 3 billion. Its defining achievement is affordability at scale: the R21/Matrix-M malaria vaccine, co-developed with the University of Oxford using Novavax’s adjuvant, is now part of routine immunisation across African countries, and a Gavi–UNICEF pricing agreement lowered the dose price to $2.99 savings Gavi estimates will fund vaccination for millions more children. The company also supplies its Cervavac HPV vaccinehttps://www.seruminstitute.com/ to India’s universal immunisation programme at a reduced price. Few manufacturers convert research into public-health reach this directly.

Sinovac

Sinovac demonstrates how a regionally rooted manufacturer earns international standing. Three of its vaccines hold WHO prequalification, the Healive hepatitis A vaccine, the Sabin-strain inactivated polio vaccine and its live attenuated varicella vaccine, the first and only varicella vaccine from China to achieve that status, which passed WHO reassessment in late 2025. That varicella vaccine has now reached close to 20 countries with nearly 30 million doses supplied, including authorisations in Argentina, Peru, Kenya, Lebanon and Indonesia. Its portfolio spans influenza, hepatitis, HFMD, polio and pneumococcal disease, with combination and recombinant candidates in development.

What this means if you are buying or supplying vaccines

For procurement teams and health ministries, the practical takeaway is that supplier choice is now a question of fit rather than size. Breadth of schedule coverage points one way, cold-chain simplicity and needle-free delivery another, and tendered cost-per-dose another again.

For manufacturers and commercial teams, our data points to where the demand is moving. Asia Pacific accounted for 32.05% of the global market in 2025 at $26.25 billion and is growing fastest at a 6.315% CAGR, with India at 7.267%. Localised production and technology partnerships, rather than export-only models, are what unlock that growth a pattern visible in every company profile above.

How we researched this

Company names and the market model come from our 8th Edition Vaccine Market Analysis, built on a 70:30 primary-to-secondary research ratio with 54 expert interviews and more than 10,400 validated data points. Every company claim in this article was then verified against a primary source regulatory approvals against FDA, EMA and WHO records, financial figures against company filings, and facility milestones against company announcements. Claims we could not verify to a primary source were left out.

The bigger picture

No single company covers the vaccine market, and that is the point. Reaching $126.379 billion by 2033 requires high-volume affordability, deep paediatric catalogues, pandemic surge capacity, platform speed and delivery convenience and no one organisation holds all five. The companies above are strong precisely because their strengths are complementary rather than interchangeable.